Obesity is a well-established risk factor for hypertension, and produces various hemodynamic abnormalities that may impact hypertension subtypes [1]. From 2011 to 2020, obesity prevalence in the US increased substantially [2]. Since 2021, the widespread adoption of novel anti-obesity therapies, such as glucagon-like peptide-1 receptor agonists, has enabled substantial short-term weight loss [3]. While long-term maintenance of normal weight benefits blood pressure control [4], the impact of short-term weight change on the risk of hypertension and its subtypes remains unclear.
